CHO-H01 of CHO Pharma Won an Award of Excellence

CHO Pharma’s CHO-H01 won “Most Promising Monoclonal Antibodies Pipeline” in Taiwan Biopharma Excellence Awards in the 10th Biological World Taiwan on October 18th and 19th, 2022. President Wu stressed CHO-H01 is the very first glycoengineered antibody drug with a single human glycan form that has entered clinical trial. We are quite satisfied with its safety profiles and low immunogenicity property in lymphoma patients.